Novo seeks to block compounders' Ozempic copies

• Many compounders produce the drugs for around $100 a month while the list price for Novo's Wegovy is more than $1,300.

Driving the news: Novo Nordisk nominated semaglutide to an FDA list of drugs that it considers complex to make and would disqualify compounders from making them, even during shortages, CNBC reports.

• "These drugs are inherently complex to compound safely, and the risks they pose to patient safety far outweigh any benefits," Novo Nordisk said in a statement.
• The Danish drugmaker has previously filed dozens of lawsuits challenging the compounders creating cheaper versions of its drugs, known as GLP-1 agonists.
• The FDA has previously issued warnings to consumers about the safety of certain compounded versions of GLP-1s.

The other side: "To me, this looks more like desperation and an attempt by Novo to protect its revenue stream than a serious scientific argument," said Alliance for Pharmacy Compounding CEO Scott Brunner in a statement.